Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab

Xiao Ni; Timothy Langridge; Madeleine Duvic

doi:10.1080/2162402X.2015.1011524

Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab

Xiao Ni, Timothy Langridge, Madeleine Duvic

Dermatology

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

The CC chemokine receptor 4 (CCR4) is highly expressed on type 2 helper T cells and regulatory T (Treg) cells. Mogamulizumab, an anti-CCR4 antibody, reduces the numbers of CCR4+ malignant T cells and CCR4⁺ Treg cells in cutaneous T-cell lymphoma. Depleting Treg cells by targeting CCR4 has great potential in cancer immunotherapies.

Original language	English (US)
Pages (from-to)	1-2
Number of pages	2
Journal	OncoImmunology
Volume	4
Issue number	7
DOIs	https://doi.org/10.1080/2162402X.2015.1011524
State	Published - Jan 1 2015

Keywords

Chemokine receptor
Cutaneous T-cell lymphoma
Mogamulizumab
Monoclonal antibody
Mycosis fungoides
Regulatory T cells
Sézary syndrome
Targeted therapy

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.1080/2162402X.2015.1011524

Cite this

@article{7faaed7ee9b44fc9aab32729b8dcd2c3,

title = "Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab",

abstract = "The CC chemokine receptor 4 (CCR4) is highly expressed on type 2 helper T cells and regulatory T (Treg) cells. Mogamulizumab, an anti-CCR4 antibody, reduces the numbers of CCR4+ malignant T cells and CCR4+ Treg cells in cutaneous T-cell lymphoma. Depleting Treg cells by targeting CCR4 has great potential in cancer immunotherapies.",

keywords = "Chemokine receptor, Cutaneous T-cell lymphoma, Mogamulizumab, Monoclonal antibody, Mycosis fungoides, Regulatory T cells, S{\'e}zary syndrome, Targeted therapy",

author = "Xiao Ni and Timothy Langridge and Madeleine Duvic",

note = "Publisher Copyright: {\textcopyright} 2015 Taylor & Francis Group, LLC.",

year = "2015",

month = jan,

day = "1",

doi = "10.1080/2162402X.2015.1011524",

language = "English (US)",

volume = "4",

pages = "1--2",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "7",

}

TY - JOUR

T1 - Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab

AU - Ni, Xiao

AU - Langridge, Timothy

AU - Duvic, Madeleine

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The CC chemokine receptor 4 (CCR4) is highly expressed on type 2 helper T cells and regulatory T (Treg) cells. Mogamulizumab, an anti-CCR4 antibody, reduces the numbers of CCR4+ malignant T cells and CCR4+ Treg cells in cutaneous T-cell lymphoma. Depleting Treg cells by targeting CCR4 has great potential in cancer immunotherapies.

AB - The CC chemokine receptor 4 (CCR4) is highly expressed on type 2 helper T cells and regulatory T (Treg) cells. Mogamulizumab, an anti-CCR4 antibody, reduces the numbers of CCR4+ malignant T cells and CCR4+ Treg cells in cutaneous T-cell lymphoma. Depleting Treg cells by targeting CCR4 has great potential in cancer immunotherapies.

KW - Chemokine receptor

KW - Cutaneous T-cell lymphoma

KW - Mogamulizumab

KW - Monoclonal antibody

KW - Mycosis fungoides

KW - Regulatory T cells

KW - Sézary syndrome

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84944454410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944454410&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1011524

DO - 10.1080/2162402X.2015.1011524

M3 - Article

C2 - 26140234

AN - SCOPUS:84944454410

SN - 2162-4011

VL - 4

SP - 1

EP - 2

JO - OncoImmunology

JF - OncoImmunology

IS - 7

ER -

Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this